Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

GlobeNewswireApr 2 08:17 ET

Express News | Appili Therapeutics Inc - Four New Funding Proposals, Totalling US$117.5 Mln, Submitted for Review

ReutersMar 18 07:23 ET

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

GlobeNewswireMar 18 07:22 ET

Express News | Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic Adi Platform, Advancing Toward First-in-Human Clinical Trials

ReutersDec 12, 2024 08:15 ET

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement With Aditxt, Inc.

GlobeNewswireNov 19, 2024 07:17 ET

Appili Therapeutics Inc: INTERIM MDA EN

SEDARNov 14, 2024 08:27 ET · Announcements